Glioblastoma (GBM) remains a highly aggressive tumor, characterized by its heterogeneity and profound ability to suppress both innate and adaptive immunity. Dendritic cell (DC) vaccines have emerged as a leading immunotherapeutic strategy to counteract this by restoring effective antigen presentation and generating tumor-specific T-cell responses. This review synthesizes two decades of preclinical and clinical research, outlining the biological rationale and translational progress of DC vaccination for GBM. Preclinical studies have been instrumental, demonstrating that the immunogenicity of the antigen cargo, such as whole tumor lysates, neoantigens, and immunogenic cell death products, critically influences DC activation and subsequent T-cell priming. Parallel advances in DC maturation protocols, including p38 inhibition and α-type-1 skewing, have further enhanced vaccine potency. Clinically, DC vaccines have consistently proven safe and capable of inducing systemic and intratumoral immune activation. Late-phase evaluation of DCVax-L has reported an overall survival advantage in newly diagnosed and recurrent GBM using externally controlled comparisons, although interpretation requires caution because of crossover, endpoint changes, patient heterogeneity, and reliance on matched external controls. However, the efficacy of DC monotherapy is often limited by GBM's immunosuppressive microenvironment, suboptimal DC trafficking, and evolving tumor antigenicity. Consequently, the future of this modality lies in rational combination strategies. Growing evidence supports integrating DC vaccines with immune checkpoint blockade, myeloid-targeted agents, and metabolic modulators to achieve durable tumor control. Coupled with advances in biomarker-driven patient selection and rapid, personalized manufacturing, DC vaccines are paving the way for a new generation of immunotherapy in GBM.
Introduction Human A(H5N8) vaccine datasets are increasingly important for pandemic preparedness because contemporary A(H5) viruses continue to circulate across animal reservoirs and occasionally infect humans, while directly observed human immunodynamic data remain limited. Sparse sampling complicates interpretation because peak timing, threshold crossing, booster dependence, and cross-reactive breadth must be inferred from only a few post-vaccination observations. Methods We performed an open-data quantitative reanalysis to determine whether a compact mechanistically constrained framework could recover interpretable homologous and heterologous humoral structure without overstating predictive performance. We combined physics-informed reconstruction with an explicit Kernel ODE comparator, semipooled subject-level analysis, stability checks, exploratory cellular correlation analysis, and external benchmarking. Results Across both MN and HI readouts, the PINN and Kernel ODE agreed on the direction of the principal between-group contrasts in early area under the curve and threshold-crossing day, while semipooled estimates were compatible with lower booster dependence and earlier peak timing in previously vaccinated individuals. Exploratory cellular analysis identified the clearest association between IFNg_H5 and CD4_H5, and an independent external H5 dataset showed coherent cross-reactive structure. However, the external CoronaVac benchmark favored the Kernel ODE, indicating that the contribution of this study is a mechanistically interpretable framework for sparse vaccine datasets rather than a universally superior predictor. Conclusions These findings support the cautious use of physics-informed reconstruction to organize sparse human vaccine serology into biologically interpretable response patterns. The proposed framework is most valuable as an interpretable sparse-data inference strategy, rather than as evidence of universal predictive superiority of PINN-based modeling.
H5N1 avian influenza is a highly pathogenic virus with significant implications for global public health due to its high mortality rate and potential for human-to-human transmission. This review explores the virology, pathogenesis, epidemiology, clinical manifestations, diagnostic approaches and management strategies for H5N1. The virus's ability to undergo genetic mutations poses an ongoing risk of increased transmissibility, necessitating continuous surveillance. Advances in vaccine development, including mRNA-based and universal influenza vaccines, provide promising avenues for prevention. Current antiviral treatments, such as neuraminidase inhibitors, remain the cornerstone of therapy, while supportive care is critical in severe cases. Public health interventions, including vaccination programs, quarantine measures and avian surveillance, are essential in controlling outbreaks. Recent reports of H5N1 infections in mammals, including dairy cattle, highlight the need for a One Health approach that integrates human, animal and environmental health strategies. Future directions emphasize the importance of global cooperation, pandemic preparedness and investment in rapid diagnostic tools and effective antiviral therapies. Continued research into viral evolution, host immune responses and novel therapeutic targets is necessary to mitigate the risks associated with H5N1. A proactive, multidisciplinary approach is crucial to preventing future outbreaks and ensuring global health security.
